Figure S1. Measurement of Bet v 1-specific immunoglobulin classes and subclasses by ELISA.

Figure S2. Development of Bet v 1-specific IgE responses in the course of prophylactic and therapeutic vaccination with Bet v 1-derived peptides.

Figure S3. Sera from peptide-vaccinated mice inhibit Bet v 1-induced effector cell degranulation in vitro.

Figure S4. VPD450-based detection of CD4+T cell proliferation in representative mice from each treatment group by FACS analysis.

Figure S5. Vaccination with hypoallergenic Bet v 1-derivatives containing T cell epitopes or wild-type Bet v 1 reduces Bet v 1-specific proliferation.

Table S1. Cytokine response of splenocytes from vaccinated mice in response to Bet v 1.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.